Magnetic resonance imaging and treatment effects of multiple sclerosis therapeutics
Citation Manager Formats
Make Comment
See Comments
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
MRI is now an important component in the diagnosis and assessment of multiple sclerosis (MS). Evidence gleaned from imaging studies has changed our understanding of the pathophysiology and natural history of the disease and has enabled physicians to visualize the effects of immunomodulatory therapies. Serial MRI following the index CNS event has clarified the evolution of MS, demonstrating that a majority of patients with clinically isolated syndromes already have dissemination of lesions in space and, based on MRI characteristics, likely also in time. Imaging studies have also shown that axonal injury and brain atrophy occur early in the disease. MRI techniques, such as magnetic resonance spectroscopy and magnetization transfer imaging, that are generally not part of the imaging sequences obtained as part of regular care have provided additional insight into the degree and extent of the effect of the disease process on the CNS, tissue repair, and the neuroprotective effects of therapeutics. These data have contributed to improved clinical decision making and treatment outcomes.
Glossary
- BBB=
- blood-brain barrier;
- BPF=
- brain parenchymal fraction;
- CDMS=
- clinically defined multiple sclerosis;
- CIS=
- clinically isolated syndrome;
- Cr=
- creatine;
- DMT=
- disease-modifying therapy;
- EDSS=
- Expanded Disability Status Scale;
- Gd=
- gadolinium;
- IFN=
- interferon;
- MRS=
- magnetic resonance spectroscopy;
- MS=
- multiple sclerosis;
- MTI=
- magnetization transfer imaging;
- MTR=
- magnetization transfer ratio;
- NAA=
- N-acetylaspartate;
- NAGM=
- normal appearing gray matter;
- NAWM=
- normal appearing white matter;
- REGARD=
- REbif vs Glatiramer Acetate in Relapsing MS Disease;
- RRMS=
- relapsing-remitting multiple sclerosis;
- SC=
- subcutaneous;
- T1-WI=
- T1-weighted imaging;
- T2-WI=
- T2-weighted imaging;
- WM=
- white matter.
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Long-term Safety and Efficacy of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease
Dr. Marianne de Visser and Dr. Maudy Theunissen
► Watch
Related Articles
- No related articles found.
Alert Me
Recommended articles
-
Articles
Evidence for neuroprotection and remyelination using imaging techniquesDouglas L. Arnold et al.Neurology, June 04, 2007 -
Articles
Relationship between inflammatory lesions and cerebral atrophy in multiple sclerosisN. D. Richert, T. Howard, J. A. Frank et al.Neurology, February 27, 2006 -
Articles
Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypesN. De Stefano, A. Giorgio, M. Battaglini et al.Neurology, June 07, 2010 -
Article
Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM studyDavid H. Miller, Robert J. Fox, J. Theodore Phillips et al.Neurology, February 13, 2015